Expression of NKRs CD94, NKG2A, CD161 and CD57 in patients maintaining or withdrawing therapy.

<p>Graphs illustrate (<b>A</b>) CD94 and NKG2A expression and (<b>B</b>) CD161 and CD57 expression at baseline (▴) and three months (○) in patients maintaining or withdrawing TNF inhibitor therapy. (C) Representative dot plots of two patients withdrawing TNF inhibitor therapy. Patient (I) remained in clinical remission for the study duration and maintained expansion of CD94 and NKG2A; Patient (II) had a flare in disease activity 6 months after withdrawal of therapy with loss of expansion of CD94 and NKG2A at 3 months (i.e. prior to clinical relapse). *p<0.05 significantly different.